Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...

Relacorilant plus nab-paclitaxel could be a new standard of care for platinum-resistant ovarian cancer, according to Alexander Olawaiye, MD.

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Following the Phase II faceoff between two of Scancell’s lead melanoma immunotherapy candidates, the biotech has selected ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

In March 2024, Lantern dosed two subjects in a Phase Ia/Ib trial of LP-284 for relapsed or refractory non-Hodgkin’s lymphoma ...

In a randomized pilot study recently published in the Journal for ImmunoTherapy of Cancer, an international research team led ...